Breast Imaging

Should You Order Axillary Ultrasound for Clinically Node-Negative Breast Cancer >2 cm?

·
Should You Order Axillary Ultrasound for Clinically Node-Negative Breast Cancer >2 cm?

A 62-year-old female is in your clinic for follow-up. Last week’s biopsy confirmed a 2.8 cm invasive ductal carcinoma in her right breast, diagnosed after a screening mammogram. On physical examination, her axilla is soft, with no palpable adenopathy. You know that accurate nodal staging is critical for determining her prognosis and treatment plan, which will likely involve surgery and may include systemic therapy or radiation. The question now is how to best evaluate her clinically negative axilla before she proceeds to the operating room. Do you rely on the clinical exam alone and proceed to sentinel lymph node biopsy, or is there a role for pre-operative imaging?

This article provides a detailed clinical workflow for this specific scenario: initial imaging of the axilla in a female with a newly diagnosed breast cancer greater than 2 cm and a clinically negative axillary exam. For this presentation, the American College of Radiology (ACR) Appropriateness Criteria rate US axilla as May be appropriate.

Who Fits This Clinical Scenario for Axillary Staging?

This guidance is tailored for a precise patient population. Applying this workflow correctly requires confirming that your patient meets all the inclusion criteria and none of the key exclusion criteria.

This workflow applies to patients who have:

  • A new diagnosis of breast cancer (e.g., invasive ductal or lobular carcinoma).
  • A primary tumor size measured to be greater than 2 cm.
  • A clinically negative axillary examination, meaning there are no palpable, firm, or fixed lymph nodes.

This workflow does NOT apply if the patient presents differently:

  • Clinically Positive Axilla: If you can palpate a suspicious (firm, matted, or fixed) lymph node, the patient fits a different scenario: Female. Newly diagnosed breast cancer, greater than 2 cm, with clinical node-positive. The pre-operative workup in that case is more aggressive, as the likelihood of nodal metastasis is high, and biopsy of the palpable node is the immediate next step.
  • Smaller Primary Tumor: If the breast cancer is 2 cm or less, the pre-test probability of axillary metastasis is lower. This falls under the scenario: Female. Newly diagnosed breast cancer, 2 cm or less, with clinical node-negative. In this group, many patients proceed directly to sentinel lymph node biopsy without pre-operative axillary imaging.
  • Primary Axillary Lump: If the patient’s initial presentation is a palpable lump in the axilla without a known breast primary, the workup is different. That scenario, Female. New palpable, unilateral, axillary lump, focuses on diagnosing the cause of the lump itself, which could be an occult breast cancer, lymphoma, or a benign process.

What Are You Evaluating with Axillary Imaging in This Cancer Staging Scenario?

In this context, imaging is not used to diagnose a symptom but to perform pre-operative staging. The goal is to identify occult (non-palpable) nodal disease that would change surgical or systemic therapy planning. The key differential consideration is whether the axillary lymph nodes are normal or harbor metastatic disease.

Occult Nodal Metastasis
This is the primary target of the investigation. For tumors larger than 2 cm, the risk of lymph node involvement increases, even when the axillary exam is negative. Identifying a suspicious node on ultrasound allows for a pre-operative, image-guided biopsy (FNA or core needle). A positive biopsy confirms N1 disease, which can alter the surgical plan from a sentinel lymph node biopsy (SLNB) to an axillary lymph node dissection (ALND) or guide neoadjuvant therapy planning. This “up-front” staging can prevent the need for a second axillary surgery if the sentinel node returns positive post-operatively.

Reactive (Benign) Adenopathy
Lymph nodes can be enlarged or prominent due to benign causes, such as recent infection, vaccination, or systemic inflammatory conditions. Ultrasound is highly effective at evaluating nodal morphology. Benign reactive nodes typically maintain their oval shape and a normal fatty hilum, whereas metastatic nodes often become rounded, lose their fatty hilum, and develop focal or diffuse cortical thickening. Imaging helps differentiate these two states and avoid unnecessary biopsies of clearly benign-appearing nodes.

Normal Lymph Nodes
The desired finding is, of course, the absence of any suspicious nodes. A normal axillary ultrasound, where all visualized nodes have a benign appearance (oval shape, thin cortex, visible fatty hilum), provides reassurance. In this case, the patient would proceed with the planned SLNB at the time of their breast surgery, which remains the gold standard for staging a clinically node-negative axilla.

Why Is Axillary Ultrasound the Go-To Study for Clinically Node-Negative Disease?

For a patient with a newly diagnosed breast cancer >2 cm and a negative clinical exam, both US axilla and MRI breast without and with IV contrast are rated as May be appropriate by the ACR. However, ultrasound is overwhelmingly the more common, practical, and cost-effective first step for dedicated axillary evaluation.

The key rationale for axillary ultrasound is its ability to provide high-resolution morphologic detail of the lymph nodes and, crucially, to guide immediate biopsy of any suspicious findings. It is a dynamic examination that can assess the entire axillary basin (levels I, II, and III) without exposing the patient to ionizing radiation (0 mSv). If a node appears abnormal—with features like a thickened cortex (>3 mm), a rounded shape, or effacement of the fatty hilum—the radiologist can perform a fine-needle aspiration (FNA) or core needle biopsy in the same session. Confirming metastasis pre-operatively provides invaluable information for the multidisciplinary team.

Why are other advanced imaging modalities rated lower?

  • FDG-PET/CT is rated Usually not appropriate for initial axillary staging in this specific scenario. While it is a powerful tool for detecting distant metastatic disease, its spatial resolution is too low to reliably detect small-volume nodal metastases or micrometastases. It also involves significant radiation exposure (☢☢☢☢ 10-30 mSv). Its role is typically reserved for patients with biopsy-proven nodal disease, inflammatory breast cancer, or clinical concern for distant metastases (Stage III or higher).
  • CT chest with IV contrast is also rated Usually not appropriate. While it can visualize bulky adenopathy, it lacks the morphologic detail of ultrasound for assessing subtle signs of early nodal involvement. It is less sensitive than ultrasound for detecting abnormal nodes and also carries a significant radiation dose (☢☢☢☢ 10-30 mSv).

While breast MRI is also rated May be appropriate, it is typically performed for evaluating the extent of disease within the breast itself (e.g., looking for additional cancer foci) rather than as a primary tool for axillary staging. Though it can visualize axillary nodes, its sensitivity for nodal metastases is variable, and it cannot be used to guide a biopsy in real-time like ultrasound can.

What’s Next After US Axilla? Downstream Workflow

The results of the axillary ultrasound create clear and distinct pathways for patient management. The primary goal is to triage the patient to the correct initial axillary surgery: sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND).

  • If the ultrasound is positive (suspicious node identified): The immediate next step is an ultrasound-guided biopsy (FNA or core) of the most abnormal-appearing node.
  • If the biopsy is positive for metastasis: The patient is now considered pathologically node-positive (pN1). This changes management significantly. She may proceed directly to ALND, or if neoadjuvant chemotherapy is planned, the positive node can be marked with a clip for targeted axillary dissection (TAD) after treatment.
  • If the biopsy is negative: Management can be complex. Depending on the degree of sonographic suspicion and the biopsy type (FNA vs. core), the patient may still proceed with a standard SLNB, as false negatives can occur. The clipped node may be targeted for removal during the SLNB.
  • If the ultrasound is negative (no suspicious nodes): The patient remains clinically node-negative. The standard of care is to proceed with SLNB at the time of breast surgery. The ultrasound provides additional confidence in this plan but does not replace the need for surgical staging.
  • If the ultrasound is indeterminate: In some cases, a node may have borderline features. The radiologist’s report will typically recommend either short-term follow-up (less common in a pre-operative setting) or biopsy to resolve the ambiguity. In most pre-operative cancer cases, any indeterminate finding will be recommended for biopsy to avoid uncertainty.

Pitfalls to Avoid (and When to Get Help)

  • Pitfall 1: Skipping Imaging Based on Exam Alone. With tumors >2 cm, the rate of occult nodal disease is significant. Relying solely on a negative physical exam may lead to under-staging and the potential need for a second surgery if the sentinel node is found to be positive.
  • Pitfall 2: Accepting a “Limited” Axillary Ultrasound. Ensure the order specifies a complete diagnostic axillary ultrasound, which includes evaluation of all nodal levels. A quick look limited to level I is insufficient for proper staging.
  • Pitfall 3: Misinterpreting a Negative Ultrasound. A negative ultrasound does not rule out micrometastatic disease. It is not a substitute for surgical staging. The patient should still be counseled that an SLNB is the definitive next step.
  • Pitfall 4: Ordering PET/CT for Initial Staging. Do not order a PET/CT for initial axillary staging in this specific patient population. It is a high-radiation, lower-resolution study for this purpose and is considered Usually not appropriate by the ACR.

If the ultrasound reveals extensive or high-level (Level II/III) adenopathy, or if there is evidence of extracapsular extension, this suggests a higher disease burden. This is a critical point to escalate care by ensuring prompt discussion at a multidisciplinary tumor board to integrate surgical, medical, and radiation oncology planning.

Related ACR Topics and Tools

This article covers one specific clinical scenario. For a comprehensive overview of all related presentations and imaging guidelines, or to explore the technical details of the recommended studies, the following resources are essential.

Frequently Asked Questions

If the axillary ultrasound is negative, can my patient skip the sentinel lymph node biopsy (SLNB)?

No. A negative axillary ultrasound is reassuring but does not have a high enough negative predictive value to replace surgical staging. It is not sensitive enough to detect microscopic metastases. The standard of care for a clinically and sonographically node-negative patient is still to proceed with an SLNB at the time of their breast surgery.

Why is breast MRI also rated ‘May be appropriate’ for this scenario?

Breast MRI is often ordered to evaluate the extent of cancer within the breast itself, such as looking for multicentric or contralateral disease. While it provides images of the axilla, it is not the primary modality for axillary staging. It is less specific than ultrasound for nodal characterization and cannot be used for real-time biopsy guidance. If a breast MRI is already being done for other reasons, the axilla will be evaluated, but a dedicated axillary ultrasound is the preferred first step for nodal staging.

What if my patient had a COVID-19 vaccine recently in the ipsilateral arm?

This is a critical piece of clinical history. Recent vaccination can cause prominent reactive (benign) lymphadenopathy in the draining axilla, which can mimic malignancy on imaging. It is essential to document the date and location of recent vaccinations. While suspicious morphologic features on ultrasound would still warrant a biopsy, the presence of benign-appearing but enlarged nodes in the setting of a recent vaccine may be interpreted as reactive, potentially avoiding an unnecessary biopsy.

Does tumor biology (e.g., triple-negative or HER2-positive) change this imaging recommendation?

While aggressive tumor subtypes like triple-negative or HER2-positive breast cancer have a higher likelihood of nodal metastasis, the initial imaging algorithm for a clinically node-negative patient remains the same: start with an axillary ultrasound. The tumor biology becomes more critical in determining the overall treatment plan, especially regarding the use and timing of neoadjuvant chemotherapy, but it does not change the choice of the initial imaging modality for the axilla.

Is there a role for CT or PET/CT if the ultrasound-guided biopsy confirms axillary metastasis?

Yes. Once nodal disease is pathologically confirmed (N1), the patient’s clinical stage is now at least Stage II. At this point, further systemic staging to look for distant metastatic disease is often warranted. In this context, a CT of the chest, abdomen, and pelvis with contrast or an FDG-PET/CT becomes appropriate to complete the staging workup before finalizing the comprehensive treatment plan.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026